



Spinal Cord Compression: Molecular, Cellular and Therapeutic Aspects

Guest Editor:

Dr. Meng-Jen Lee

Department of Applied
Chemistry, Chaoyang University
of Technology, Taichung 413310,
Taiwan

Deadline for manuscript
submissions:

closed (31 July 2024)

Message from the Guest Editor

Spinal cord compression could result from both atraumatic and traumatic causes. Despite the protection from the spinal vertebra, occasionally, the spinal cord is faced with an assortment of compressive forces that are caused by blood clots, neoplastic growth, infections, ectopic bone growth, or the protrusion of intervertebral discs within the restricted area of the spinal epidural space and meninges. A more drastic compression force comes from falls, traffic accidents, sports injuries, etc. To date, the only available therapy has involved drastic surgery and the systematic use of drugs, and surgery was only aided by medical examinations rather than images. The molecular and cellular study of spinal cord compression would benefit from the identification of biomarkers, which could be used as a diagnostic indication and/or a drug target for new therapies.

This Special Issue of *Biomedicines* focuses on recent advances in the characterization of molecular and cellular events that are involved in spinal cord compression. These may provide valuable information for the diagnosis as well as treatment of the injury.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI